Closed to Patient Entry

Date of activation: 30-Jul-2019
Date Step1 close: 31-Aug-2021

Yes

Phase 2
Not randomized / N.A.

EORTC Groups: 150 - All Groups: 150

Radiotherapy, Drug
Cyclophosphamide, Dacarbazine, Doxorubicin, Etoposide, Vinblastine, Dexamethasone, Brentuximab vedotin

• Martin Hutchings (Study Coordinator), Rigshospitalet, Copenhagen
• Sarah Nuyens (Project Manager), EORTC Headquarters, Brussels
• Ward Sents (Clinical Scientist), EORTC Headquarters, Brussels
• Lydia Champezou (Statistician), EORTC Headquarters, Brussels
• Cedric Mallien (TR Scientist), EORTC Headquarters, Brussels
• Laila Ben Salama (Clinical Operations Manager), EORTC Headquarters, Brussels
• Shani De Coster (Data Manager), EORTC Headquarters, Brussels
• Axelle Nzokirantevye (Imaging DM), EORTC Headquarters, Brussels
• Leen Wijnen (Imaging DM), EORTC Headquarters, Brussels
• Bart Meulemans (Clinical Data Expert), EORTC Headquarters, Brussels
• Zara Nasir (Pharmacovigilance Manager), EORTC Headquarters, Brussels
• Jelle Stans (Regulatory Affairs Manager), EORTC Headquarters, Brussels
• Miguel Remis (Lead CRA), EORTC Headquarters, Brussels
• Stefanos Soraruff (Clinical Operations Assistant), EORTC Headquarters, Brussels
• Hafida Lmalem (Imaging Officer), EORTC Headquarters, Brussels
• Lucy Sepulveda (Regulatory Affairs Administrator), EORTC Headquarters, Brussels
• Laure Musekera (Statistical Fellow), EORTC Headquarters, Brussels
• Enrico Clementel (RTQA Manager), EORTC Headquarters, Brussels
• Catherine Fortpied (Lead Statistician), EORTC Headquarters, Brussels

• Hodgkins Disease

• EORTC Lymphoma Group

• Amsterdam UMC stichting - Locatie AMC (Amsterdam, Netherlands)
• Deventer Ziekenhuis (Deventer, Netherlands)
• Erasmus MC (Rotterdam, Netherlands)
• Haaglanden MC - locatie Antoniushove ( Leidschendam, Netherlands)
• Hospital Universitario de Navarra (Pamplona, Spain)
• ICO L’Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia) (L' Hospitalet De Llobregat, Spain)
• Instituto Portugues de Oncologia de Lisboa Francisco Gentil – EPE (Lisboa, Portugal)
• Maria Sklodowska-Curie National Research Institute of Oncology (Warsaw, Poland)
• Maxima Medisch Centrum - Locatie Veldhoven (Veldhoven, Netherlands)
• Medisch Centrum Leeuwarden-Zuid (Leeuwarden, Netherlands)
• Narodny Onkologicky Ustav - Bratislava (Bratislava, Slovakia)
• Radboud University Medical Center Nijmegen (Nijmegen, Netherlands)
• Rigshospitalet (Copenhagen, Denmark)
• U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium)
• Universitair Ziekenhuis Antwerpen (Edegem, Belgium)
• University Medical Center Groningen (Groningen, Netherlands)
• ZAS CADIX (Antwerpen, Belgium)

http://clinicaltrials.gov/study/NCT03517137

NCT03517137

2017-000498-35